论文部分内容阅读
2例年龄分别为32和43岁的男性慢性乙型肝炎患者口服阿德福韦酯10 mg/d治疗,随后出现肾小管损伤,包括血磷下降。例1在治疗236周时,血清肌酐(SCr)158μmol/L,尿素氮(BUN)4.04 mmol/L,血磷0.67 mmol/L,肌酐清除率(Ccr)47.6 ml/min。例2在治疗65周时,SCr 141μmol/L,BUN 6.59 mmol/L,血磷0.68 mmol/L,Ccr 48.7 ml/min。2例患者尿常规检查均正常,尿量正常,且无全身性水肿。根据Ccr,阿德福韦酯改为10 mg,隔日1次。12周后,2例患者SCr和BUN下降或正常。
Two male CHB patients aged 32 and 43 years were treated with oral adefovir dipivoxil at a dose of 10 mg / d followed by renal tubular damage, including a decrease in serum phosphate. Example 1 Serum creatinine (SCr) of 158 μmol / L, BUN 4.04 mmol / L, phosphorus 0.67 mmol / L and creatinine clearance (Ccr) of 47.6 ml / min at 236 weeks of treatment. Example 2 At 65 weeks of treatment, SCr 141 μmol / L, BUN 6.59 mmol / L, Phosphorus 0.68 mmol / L, Ccr 48.7 ml / min. Urine routine examination was normal in 2 patients, urine output was normal, and no systemic edema. According to Ccr, adefovir dipivoxil was changed to 10 mg every other day. Twelve weeks later, SCr and BUN decreased or were normal in 2 patients.